Skip to main content

Advertisement

Log in

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1

References

  1. Dombret H, Gardin C . An update of current treatments for adult acute myeloid leukemia. Blood 2016; 127: 53–61.

    Article  CAS  Google Scholar 

  2. Cornelissen JJ, Blaise D . Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016; 127: 62–70.

    Article  CAS  Google Scholar 

  3. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264–278.

    Article  CAS  Google Scholar 

  4. Zhang M, Sukhumalchandra P, Enyenihi AA St, John LS, Hunsucker SA, Mittendorf EA et al. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res 2013; 19: 247–257.

    Article  CAS  Google Scholar 

  5. Sergeeva A, He H, Ruisaard K St, John L, Alatrash G, Clise-Dwyer K et al. Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo. Leukemia 2016; 30: 1475–1484.

    Article  CAS  Google Scholar 

  6. Garwicz D, Lennartsson A, Jacobsen SE, Gullberg U, Lindmark A . Biosynthetic profiles of neutrophil serine proteases in a human bone marrow-derived cellular myeloid differentiation model. Haematologica 2005; 90: 38–44.

    CAS  PubMed  Google Scholar 

  7. Gorodkiewicz E, Sienczyk M, Regulska E, Grzywa R, Pietrusewicz E, Lesner A et al. Surface plasmon resonance imaging biosensor for cathepsin G based on a potent inhibitor: development and applications. Anal Biochem 2012; 423: 218–223.

    Article  CAS  Google Scholar 

  8. Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, Sconocchia G et al. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res 2005; 11: 4495–4503.

    Article  CAS  Google Scholar 

  9. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA et al. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood 2011; 117: 780–787.

    Article  CAS  Google Scholar 

  10. Wilson TJ, Nannuru KC, Futakuchi M, Singh RK . Cathepsin G-mediated enhanced TGF-beta signaling promotes angiogenesis via upregulation of VEGF and MCP-1. Cancer Lett 2010; 288: 162–169.

    Article  CAS  Google Scholar 

  11. Bacher U, Haferlach T, Alpermann T, Kern W, Schnittger S, Haferlach C . Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype. Leukemia 2013; 27: 496–500.

    Article  CAS  Google Scholar 

  12. Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011; 117: 4262–4272.

    Article  CAS  Google Scholar 

  13. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 2002; 116: 409–420.

    Article  CAS  Google Scholar 

  14. Yu FX, Zhao B, Guan KL . Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 2015; 163: 811–828.

    Article  CAS  Google Scholar 

  15. Ogawa S, Yokoyama Y, Suzukawa K, Nanmoku T, Kurita N, Seki M et al. Identification of a fusion gene composed of a Hippo pathway gene MST2 and a common translocation partner ETV6 in a recurrent translocation t(8;12)(q22;p13) in acute myeloid leukemia. Ann Hematol 2015; 94: 1431–1433.

    Article  Google Scholar 

Download references

Acknowledgements

This work is supported by grants from the Leukemia Research Foundation (GA), National Institutes of Health National Cancer Institute (P50CA100632) (GA) and Leukemia & Lymphoma Society (GA and SK).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G Alatrash.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alatrash, G., Garber, H., Zhang, M. et al. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia 31, 234–237 (2017). https://doi.org/10.1038/leu.2016.249

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.249

  • Springer Nature Limited

This article is cited by

Navigation